Remove 2005 Remove Invention Remove Marketing Remove Patent Infringement
article thumbnail

Claim Construction Order Sets Stage for Moderna v. Pfizer Vaccine Patent Showdown

Patently-O

by Dennis Crouch Moderna filed a patent infringement lawsuit against Pfizer and BioNTech in August 2022, alleging that the defendants COVID-19 vaccine infringes three patents related to Moderna’s mRNA vaccine technology. United States Patent Nos. 2005) (en banc). 10,898,574, 10,702,600, and 10,933,127.

Patent 97
article thumbnail

Federal Circuit Debates Scope of 271(e)(1) Safe Harbor and the Meaning of “Solely”

Patently-O

highlights tensions in the court’s interpretation of the patent infringement safe harbor under 35 U.S.C. § 271(e)(1) provides an exemption from patent infringement liability for certain activities related to seeking regulatory approval of drugs and medical devices. 193 (2005). 193 (2005). 271(e)(1).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Biogen Seeks a Preliminary Injunction in Natalizumab BPCIA Case Against Sandoz

LexBlog IP

Biogen alleges infringement of twenty-eight patents under the BPCIA based on Sandoz’s submission of an aBLA for PB006, a proposed biosimilar of TYSABRI (natilizumab). ” Biogen seeks a judgment that Sandoz and Polpharma have infringed or will infringe the asserted patents, and preliminary and permanent injunctive relief. .”

article thumbnail

IP as Collateral

IIPRD

The risks include unauthorised use and infringement, technological obsolescence, and the marketable nature of IP as collateral. Instances of companies using IP as collateral during times of distress are as follows: Xerox pledged its Patents as collateral due to problems faced concerning financial fraud and certain distress in 2002.

IP 40